Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-614-5220
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees215
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions
What is Aimmune Therapeutics' stock symbol?
Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."
How were Aimmune Therapeutics' earnings last quarter?
Aimmune Therapeutics Inc (NASDAQ:AIMT) released its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.92) by $0.03. View Aimmune Therapeutics' Earnings History.
When is Aimmune Therapeutics' next earnings date?
What price target have analysts set for AIMT?
7 Wall Street analysts have issued twelve-month price targets for Aimmune Therapeutics' shares. Their forecasts range from $30.01 to $80.00. On average, they anticipate Aimmune Therapeutics' share price to reach $48.5729 in the next twelve months. This suggests a possible upside of 120.2% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.
What is the consensus analysts' recommendation for Aimmune Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.
What are Wall Street analysts saying about Aimmune Therapeutics stock?
Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
- 1. Wedbush analysts commented, "SPRO announced that SPR720, an orally administered antimicrobial agent being developed for the treatment of non-tuberculous mycobacterial (NTM) infections, has been granted Product (QIDP) designation by the FDA. SPR720 is currently being evaluated in a Ph1 placebo-controlled clinical trial assessing safety, tolerability, and PK in healthy volunteers (data in 2H19). We’re encouraged by the significant progress at SPRO, especially in regards to: 1) FDA acceptance of an IND for SPR994, 2) meeting with FDA indicating that a single pivotal trial (ADAPT-PO) could support registration of SPR994, 3) nearterm initiation of the SPR994 Ph3 study which is posted on SAD/MAD data for SPR206 potentiator for gram-negative infections and SPR720 data in 2H19." (2/26/2019)
- 2. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (2/4/2019)
- 3. Cantor Fitzgerald analysts commented, ". We are assuming coverage of AIMT with an Overweight rating and a 12-month PT of $64 based on lead asset AR101 in peanut allergy. Given the growing unmet clinical need in PA, ‘101 has Track designations, and we believe a high regulatory PoS exists based on data from the P3 PALISADE study. Full study data were recently published in the NEJM, validating the results and further enhancing our conviction given the notably reduced use of rescue epinephrine during the DBPCFC and limited use during updosing." (12/2/2018)
Has Aimmune Therapeutics been receiving favorable news coverage?
News headlines about AIMT stock have been trending positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aimmune Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Aimmune Therapeutics' key competitors?
Some companies that are related to Aimmune Therapeutics include Alkermes (ALKS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH), Patheon (PTHN), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY), Horizon Pharma (HZNP), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX), TESARO (TSRO), HUTCHISON CHINA/S (HCM), ACADIA Pharmaceuticals (ACAD) and Evotec (EVTCY).
What other stocks do shareholders of Aimmune Therapeutics own?
Who are Aimmune Therapeutics' key executives?
Aimmune Therapeutics' management team includes the folowing people:
- Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
- Mr. Jeffrey H. Knapp, Chief Operating Officer (Age 53)
- Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
- Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)
- Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
When did Aimmune Therapeutics IPO?
(AIMT) raised $124 million in an initial public offering (IPO) on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.
Who are Aimmune Therapeutics' major shareholders?
Aimmune Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.34%), Foresite Capital Management II LLC (5.05%), FMR LLC (3.57%), Eagle Asset Management Inc. (2.24%), Victory Capital Management Inc. (1.62%) and Emerald Advisers LLC (1.26%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly, Susan E Barrowcliffe and Warren L Desouza. View Institutional Ownership Trends for Aimmune Therapeutics.
Which major investors are selling Aimmune Therapeutics stock?
AIMT stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, BlackRock Inc., Foresite Capital Management III LLC, Barclays PLC, Sofinnova Investments Inc., Jennison Associates LLC, RMB Capital Management LLC and Eagle Asset Management Inc.. Company insiders that have sold Aimmune Therapeutics company stock in the last year include Douglas T Sheehy and Stephen George Dilly. View Insider Buying and Selling for Aimmune Therapeutics.
Which major investors are buying Aimmune Therapeutics stock?
AIMT stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Emerald Advisers LLC, Norges Bank, Victory Capital Management Inc., Emerald Mutual Fund Advisers Trust, Opaleye Management Inc., SG Americas Securities LLC and Massachusetts Financial Services Co. MA. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.
How do I buy shares of Aimmune Therapeutics?
Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aimmune Therapeutics' stock price today?
One share of AIMT stock can currently be purchased for approximately $22.06.
How big of a company is Aimmune Therapeutics?
Aimmune Therapeutics has a market capitalization of $1.37 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 215 workers across the globe.
What is Aimmune Therapeutics' official website?
How can I contact Aimmune Therapeutics?
Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]
MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
